z-logo
Premium
Main B‐cell epitopes of PvAMA‐1 and PvMSP‐9 are targeted by naturally acquired antibodies and epitope‐specific memory cells in acute and convalescent phases of vivax malaria
Author(s) -
Soares Roberta Reis,
Nakaie Clovis Ryuichi,
RodriguesdaSilva Rodrigo Nunes,
Silva Rogério Lauria,
LimaJunior Josué da Costa,
Scopel Kézia Katiani Gorza
Publication year - 2020
Publication title -
parasite immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 75
eISSN - 1365-3024
pISSN - 0141-9838
DOI - 10.1111/pim.12705
Subject(s) - epitope , antibody , plasmodium vivax , immunology , biology , antigen , malaria , virology , b cell , immunity , humoral immunity , immune system , t cell , plasmodium falciparum
Although antibodies are considered critical for malaria protection, little is known about the mechanisms/factors that maintain humoral immunity, especially regarding the induction and maintenance of memory B cells over time. In Brazilian endemic areas, this is the first time that the profile of antibody responses and the occurrence of antigen‐specific memory B cells (MBC) against P vivax were investigated during acute malaria and up to six months after parasite clearance. For this, we selected two peptides, PvAMA‐1 (S290‐K307) and PvMSP‐9 (E795‐A808) , which represent the apical membrane antigen‐1 and merozoite surface protein‐9 of P vivax , respectively. Both peptides were previously described as containing linear B‐cell epitopes. Our findings were as follows: 1—both peptides were recognized by IgG antibodies at a high frequency (between 24% and 81%) in all study groups; 2—in the absence of infection, the IgG levels remained stable throughout 6 months of follow‐up; and 3—PvAMA‐1 (S290‐K307) and PvMSP‐9 (E795‐A808) ‐specific MBCs were detected in all individual groups in the absence of reinfection throughout the follow‐up period, suggesting long‐lived MBC. However, no positive association was observed between malaria‐specific antibody levels and frequency of MBCs over time. Taken together, these results suggest that peptides can be, in the future, an alternative strategy to polypeptidic vaccine formulation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here